VOLITIONRX LTD - Common Stock, par value $0.001 per share (VNRX)
CUSIP: 928661107
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 129,251,202
- Total 13F shares
- 7,992,589
- Share change
- +206,919
- Total reported value
- $4,835,640
- Put/Call ratio
- 0.56%
- Price per share
- $0.60
- Number of holders
- 25
- Value change
- +$105,463
- Number of buys
- 13
- Number of sells
- 9
Quarterly Holders Quick Answers
What is CUSIP 928661107?
CUSIP 928661107 identifies VNRX - VOLITIONRX LTD - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 928661107:
Top shareholders of VNRX - VOLITIONRX LTD - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Eight Corp Ltd |
3/4/5
|
10%+ Owner |
—
mixed-class rows
|
24,030,664
mixed-class rows
|
$20,785,825 | — | 02 Jan 2024 | |
| Lagoda Investment Management, L.P. |
13F
|
Company |
3.9%
|
5,073,242
|
$3,840,444 | — | 31 Mar 2024 | |
| Martin Charles Faulkes |
3/4/5
|
Executive Director, Director |
—
class O/S missing
|
2,096,207
|
$1,739,852 | — | 24 Jan 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.49%
|
636,167
|
$481,579 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.48%
|
617,366
|
$467,464 | — | 31 Mar 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.44%
|
573,760
|
$434,336 | — | 31 Mar 2024 | |
| Edward Futcher |
3/4/5
|
Director |
—
class O/S missing
|
436,436
|
$362,242 | — | 24 Jan 2024 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.13%
|
174,180
|
$131,854 | — | 31 Mar 2024 | |
| Silverberg Bernstein Capital Management LLC |
13F
|
Company |
0.11%
|
144,618
|
$109,476 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.1%
|
134,000
|
$101,438 | — | 31 Mar 2024 | |
| STATE STREET CORP |
13F
|
Company |
0.1%
|
123,923
|
$93,810 | — | 31 Mar 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.07%
|
89,389
|
$67,667 | — | 31 Mar 2024 | |
| Spectrum Asset Management, Inc. (NB/CA) |
13F
|
Company |
0.04%
|
55,596
|
$42,087 | — | 31 Mar 2024 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.04%
|
50,076
|
$37,908 | — | 31 Mar 2024 | |
| Jason Bradley Terrell MD |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
33,192
|
$27,550 | — | 03 Aug 2022 | |
| Richard Brudnick |
3/4/5
|
Director |
—
class O/S missing
|
27,936
|
$23,187 | — | 12 Jan 2023 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0.02%
|
30,020
|
$22,814 | — | 31 Mar 2024 | |
| UBS Group AG |
13F
|
Company |
0.02%
|
28,458
|
$21,543 | — | 31 Mar 2024 | |
| TWO SIGMA SECURITIES, LLC |
13F
|
Company |
0.02%
|
22,682
|
$17,170 | — | 31 Mar 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.01%
|
15,384
|
$11,646 | — | 31 Mar 2024 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0%
|
6,344
|
$4,802 | — | 31 Mar 2024 | |
| Hartford Financial Management Inc. |
13F
|
Company |
0%
|
5,000
|
$3,785 | — | 31 Mar 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
2,526
|
$1,912 | — | 31 Mar 2024 | |
| Founders Capital Management |
13F
|
Company |
0%
|
2,000
|
$1,514 | — | 31 Mar 2024 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
474
|
$359 | — | 31 Mar 2024 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0%
|
265
|
$201 | — | 31 Mar 2024 | |
| Allworth Financial LP |
13F
|
Company |
0%
|
200
|
$152 | — | 31 Mar 2024 |
Institutional Holders of VOLITIONRX LTD - Common Stock, par value $0.001 per share (VNRX) as of Q2 2024
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.